DIVISION OF IMMUNOLOGY

Please note:

	SCIENTIFIC REVIEWER FORM			
	SCIENTIFIC REVIEWER FORM			
ase	note:			
	Protocols submitted to the CTSU do not require additional Division review			
> Three-year rewrites of BCH protocols do not require review providing they reviewed initially by the Division				
nt	ific Reviewer:			

Scientific Reviewe **Date of Review:** Principal Investigator: Protocol Title: Protocol #: RETURN COMMENTS **DIRECTLY TO THE PI** BY: If no follow-up action is required by the PI, you may return the form to Jeanne Testa.

ITEMS	ASSESSMENT	COMMENTS
Scientific Review		
Are the specific aims and corresponding hypotheses clearly stated?	☐ YES ☐ NO	
Is the primary outcome (and secondary outcomes as appropriate) stated and defined?	☐ YES ☐ NO	
Has an appropriate literature search been performed such that that the rationale for the study has been adequately presented? *When risks to the subject are high, an extensive search is essential.	☐ YES ☐ NO	
Is the question or hypothesis being tested providing important knowledge to the field?	☐ YES ☐ NO	
Are there adequate preliminary data in the literature (or from the investigator) to justify the research?	☐ YES ☐ NO	
Is it feasible or reasonable to achieve the results in the proposed timeframe, including the ability to recruit, retain, or follow subjects?	☐ YES ☐ NO	

Items	Assessment	COMMENTS		
Scientific Review				
Are all the proposed tests or measurements requested necessary to answer the scientific question?	☐ YES ☐ NO			
Are the individuals who are conducting the trial properly qualified and trained to perform the procedures included in the protocol?	☐ YES ☐ NO			
Does the research present risk to the subjects?	☐ YES ☐ NO			
→ If YES, is it acceptable?	☐ YES ☐ NO			
How do the risks of the new treatment/therapy compare to standard treatment/therapies?	☐ Greater ☐ About Same ☐ Lower			
Is any standard of care denied as part of this study? → If YES, specify.	☐ YES ☐ NO			
If the protocol includes a placebo that might entail risk (even if not great), is the placebo essential for the conduct of the trial?	☐ YES ☐ NO			
→ Have/Should other study designs been/be considered?	☐ YES ☐ NO			
Are there appropriate inclusion of gender, minorities and children?	☐ YES ☐ NO			
Reviewer's overall assessment		eviewer's overa		
Please check one of the following:	PI	ease check one of	2	
This protocol is acceptable in its present format.This protocol is acceptable, pending clarifications		1.0 - 1.3	Outstanding Excellent	
from the Principal Investigator (list below)		1.0 - 2.0	Very Good	
This protocol is NOT acceptable for the reasons			Good	
stated below			Acceptable	
		Un-scored	Unacceptable	
Reviewer's other comments/questions				
☐ Follow-up action or response is required☐ The following is a recommendation only (no follow-up required)				

Reviewer's other comments/questions—Continued	
Reviewer Signature	
Principal Investigator's Responses & Correspondence	
Designated Scientific Approval Signature	Date